TCR² Therapeutics
Latest round
- Series B
Last raised
- Mar 2018
Total raised
- $170M
Investors
- 15
About TCR² Therapeutics
Founded in 2015 and based in Massachusetts, US, TCR2 Therapeutics Inc. is a company that engages in developing therapies and signaling T cells for cancer treatment. The company develops The TRuC™ Platform, a novel T cell therapy platform, which uses the complete T cell receptor (TCR) complex without the need for human leukocyte antigen (HLA) matching.
Who invested in TCR² Therapeutics
15 investors across 2 rounds
See all investors in TCR² Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about TCR² Therapeutics
Who invested in TCR² Therapeutics?
TCR² Therapeutics has 15 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TCR² Therapeutics raised?
TCR² Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did TCR² Therapeutics last raise money?
TCR² Therapeutics's most recent round on record is a Series B, in Mar 2018.
What does TCR² Therapeutics do?
Founded in 2015 and based in Massachusetts, US, TCR2 Therapeutics Inc.
Where is TCR² Therapeutics headquartered?
TCR² Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like TCR² Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at TCR² Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like TCR² Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.